Subscribe free!

Find out why we're the #1 free penny stock alert newsletter


Penny Stock on Watch: Advanced Cell Technology Inc. (ACTC)

| |

Shares of Advanced Cell Technology Inc. (OTC: ACTC), a biotechnology company applying cellular technology in the field of regenerative medicine, fell sharply in Wednesday’s trading session.

The penny stock of ACTC ended the day 7.55% lower at $0.0845. Despite the sharp decline in Wednesday’s trading session, ACTC has gained 5.23% in the last five trading sessions.

ACTC CEO Gary Rabin recently presented at the 14th Annual Rodman & Renshaw Global Investment Conference. As one of the few companies engaged in embryonic stem cell research, ACTC has generated significant interest among investors. However, the field of stem cell research remains controversial.

Recently, ACTC commented on U.S. Appeals’ Court’s dismissal ruling in case challenging federal funding of embryonic stem cell research. ACTC CEO Rabin said that the court ruling should be of considerable benefit to the company and its embryonic stem cell-based clinical programs. Rabin said that the ruling effectively removes major speed bumps for the National Institutes of Health in terms of approving the several stem cell lines that ACTC has submitted for their consideration for funding.

Rabin also said that the ruling removes a great deal of ambiguity that has hampered legislative attempts to provide an efficient mechanism for federal funding of hESC research. He added that the path for legislators to enact such legislation has now been cleared and in that case ACTC is optimistic that there could be encouraging new developments in the legislative arena, as well, in coming months.

Despite the controversies surrounding stem cell research, ACTC has made significant progress in its clinical trials. During the second quarter of 2012, ACTC added Massachusetts Eye and Ear as additional site for Clinical Trial for Dry Age-Related Macular Degeneration using embryonic stem cell-derived retinal pigment epithelial (RPE) cells. ACTC also received Data Safety Monitoring Board’s approval to increase RPE dosage for Stargardt’s Disease patients in U.S. trial.

Posted by on Thursday, September 13th, 2012. Filed under Internet, Mobile. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of BlueWave Advisors.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Leave a Reply